All In MedTech

FDA Clearance Tracker · P040013-S024

GEM21S Growth Factor Enhanced Matrix

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 4, 2020 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P040013-S024
Device name
GEM21S Growth Factor Enhanced Matrix
Applicant location
Franklin, TN
Received
Apr 17, 2020
Decided
Dec 4, 2020
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P040013

Device type

Device class
Class III
Regulation
21 CFR 872.3930

Every decision under product code NPZ

FDA's approval statement

As written in FDA's record.

Change in supplier for the formulation, filling, and testing (with the exception of the Bioassay) of the rhPDGF-BB syringe component of GEM21S Growth Factor Enhanced Matrix to a manufacturing site located at Pyramid Laboratories, Inc., 3598 Cadillac Ave., Costa Mesa, CA 92626.

Source documents

Other decisions for Lynch Biologics, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.